HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
HanAll will expand R&D investments to advance its late-stage pipeline assets SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, today reported the financial results for the first quarter...
United Imaging Healthcare bags Healthcare Asia Medtech Award
SHANGHAI, April 28, 2022 /PRNewswire/ -- United Imaging Healthcare was recognised with the Imaging Product Innovation of the Year Award at the Healthcare Asia Medtech Awards with its three groundbreaking products: the Total-body PET/CT uEXPLORER, the 3.0T uMR Omega, and uRT-linac 506c. United Imaging Healthcare is at the forefront of medical technology, closely working with hospitals, universities, and research...
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing of first patient in China Phase I Study of TST002 for the treatment of osteoporosis. This Phase I clinical trial is a randomized and double-blind,...
The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine
The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, within Denmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enables secure analysis over sensitive datasets for researchers and interconnects such large patient cohorts worldwide, today...
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress
Infertile women continue to be marginalised and excluded from treatment in developing countries SINGAPORE, April 28, 2022 /PRNewswire/ -- Women living with infertility in many developing countries are victims of a systemic process of cultural and institutional exclusion from assisted reproductive treatment. This view on access to and quality of infertility treatment...
WuXi Biologics’ 2021 ESG Report Reveals Company’s Strong Commitment to Overall Sustainability
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. - One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enabling nearly 30 Investigational New Drug Applications (INDs) for COVID-19 projects, manufacturing more than 1500kg of...
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, April 28, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving the company's five novel drug candidates will be presented at the 2022 American...
HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore
SINGAPORE and SYDNEY and NEW YORK, April 28, 2022 /PRNewswire/ -- HealthBeatsTM, a Singapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of a US$3m Seed round led by healthcare investor Heritas Capital together with SEEDS Capital, the investment arm of government agency Enterprise Singapore. The HealthBeatsTM Remote Vitals...
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session The protocol pre-specified interim overall survival analysis results from GEMSTONE-302 study of sugemalimab will be presented in a poster session. Sugemalimab is...
Zimmer Biomet’s mymobility is recognized as “The Care Management Initiative of the Year” by the 2022 Healthcare Asia Medtech Awards
SINGAPORE, April 28, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the company's mymobility® digital care management platform won "The Care Management Initiative of the Year" award at this year's Healthcare Asia Medtech Awards. mymobility® is a digital care management platform that...
